{"product_id":"gorer-viabilr-short-wire-biliary-endoprosthesis-no-holes-8-00-x-80-00mm","title":"GORE® VIABIL® Short Wire Biliary Endoprosthesis No Holes 8.00 X 80.00mm","description":"\u003cp\u003e\u003cstrong\u003eNew\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eOverview:\u003c\/p\u003e\n\u003cp\u003eDemonstrated low migrations Fully covered anti-migration fins securely hold the device within the duct to minimize the risk of migration, with a reported 0.0–1.4% migration rate range. This outperforms BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent migration rates, which ranged 0–13%.1 Higher primary patency GORE® VIABIL® Biliary Endoprosthesis offers substantiated evidence in studies that demonstrate sustained long-term patency. Clinical performance demonstrates GORE® VIABIL® maintains higher primary patency than the leading competitor at 3, 6, and 12-months.2,3 Improved long term patency can mean an improved quality of life for patients. Optimal Conformability GORE® VIABIL® Biliary Endoprosthesis offers the optimal balance of radial and axial forces, providing the right fit and flexibility to help prevent migration and sludge formation.4,5 Durable Liner A durable, non-porous FEP\/ePTFE liner prevents tissue ingrowth, promotes conformability and supports superior primary patency rates. Backed by the CONMED Biliary Assurance Program With a 0.2% average reported migration rate, we’re so confident in these outcomes that we will replace it if a migration occurs.6,7 1 W. L. Gore \u0026amp; Associates, Inc. Migration Summary for GORE® VIABIL® Biliary Endoprosthesis and BOSTON SCIENTIFIC WALLFLEX Biliary RX Fully Covered Stent. Flagstaff, AZ: W. L. Gore \u0026amp; Associates, Inc; 2017. [Literature Summary]. AW0010-EN3 2 Kitano M, Yamashita Y, Tanaka K, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol. 2013 Nov;108(11):1713-22. 3 Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovascular \u0026amp; Interventional Radiology 2010;33(1):97-106. 4 Isayama H, Mukai T, Itoi T, et al. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction: the WATCH study. Gastrointestinal Endoscopy 2012;76(1):84-92. 5 Isayama H, Nakai Y, Toyokawa Y, et al. Measurement of radial and axial forces of biliary self-expandable metallic stents. Gastrointestinal Endoscopy 2009;70(1):37-44. 7 W. L. Gore \u0026amp; Associates, Inc. Reduce the risk of reintervention. GORE® VIABIL® Biliary Endoprosthesis Assurance Brochure. Flagstaff, AZ: W. L. Gore \u0026amp; Associates, Inc.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eProduct Information:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManufacturer: Conmed\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"MRP.io","offers":[{"title":"Default Title","offer_id":46850595356812,"sku":"conmed_VSWVN0808","price":3920.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0743\/4659\/4444\/files\/biliaryeusgoreviabilproductlinkdesktop_1_1.png?v=1774381239","url":"https:\/\/www.mrp.io\/products\/gorer-viabilr-short-wire-biliary-endoprosthesis-no-holes-8-00-x-80-00mm","provider":"MRP.io","version":"1.0","type":"link"}